NantKwest Hosting Key Opinion Leader Meeting on Novel Immunotherapeutic Approaches to Address the Unmet Medical Needs of Pati...
27 11월 2019 - 10:00PM
Business Wire
NantKwest, Inc. (Nasdaq: NK), a next generation, clinical-stage
immunotherapy company focused on harnessing the unique power of our
immune system using natural killer (NK) cells to treat cancer,
infectious diseases and other diseases, today announced that on
Monday, December 2, 2019, it will host a key opinion leader (KOL)
meeting in New York City on the current treatment landscapes and
unmet medical needs of patients with Merkel cell carcinoma,
triple-negative breast cancer, solid tumors and the
state-of-the-art treatment in the induction of Immunogenic Cell
Death.
This event will feature presentations from KOLs George Ansstas,
MD, Washington University of Medicine in St. Louis, Chaitali
Nangia, MD, Chan Soon-Shiong Institute for Medicine, and Clint
Allen, MD, Johns Hopkins Kimmel Cancer Center, as well as Dr.
Patrick Soon-Shiong, Chief Executive Officer and Chairman of
NantKwest.
NantKwest’s management team will also provide pipeline updates
on their haNK and PD-L1.t-haNK programs utilizing the Company’s
Activated Natural Killer (aNK) cell platform to target these
diseases. This platform harnesses the power of the innate immune
system and is uniquely positioned to provide broadly available,
off-the-shelf cell therapies capable of being administered in the
outpatient setting.
Clint Allen, MD is an Associate Professor of Otolaryngology-Head
and Neck Surgery at the Johns Hopkins School of Medicine, Principal
Investigator of the Translational Tumor Immunology Program,
National Institute on Deafness and Other Communication Disorders,
NIH. His research focuses on understanding how the immune system
responds to squamous cell carcinoma of the head and neck, and how
this can be enhanced therapeutically. He leads a large pre-clinical
and clinical laboratory program focused on translational
pre-clinical studies in syngeneic models of squamous cell carcinoma
and the assessment of clinical trial specimens. He is the director
of the inpatient Otolaryngology consultation service at the NIH
Clinical Center and maintains a surgical practice for the Johns
Hopkins School of Medicine based out of Suburban Hospital in
Bethesda, MD.
George Ansstas, MD is an Assistant Professor of Medicine,
Section of Medical Oncology, Division of Oncology at Washington
University School of Medicine. Dr. Ansstas's clinical expertise
includes brain tumors, neuro-oncology, skin cancer, and melanoma.
He received his medical degree from University of Tishreen,
Latakia, Syria in 2001. Dr. Ansstas completed a fellowship in
hematology and oncology at Washington University, St. Louis.
Chaitali Nangia, MD is an Hematologist/Oncologist based in Costa
Mesa, California and is affiliated with Hoag Hospital System. She
received her medical degree from Lady Hardinge Medical College in
New Delhi, India and completed her residency in Internal Medicine
at Resurrection Westlake Medical Center in Illinois. She then
completed her Fellowship in Hematology/Oncology at the Henry Ford
Hospital in Michigan. She worked as an Associate Professor at
University of California-Irvine and as an Associate Program
Director at University of California-Irvine Hematology/Oncology
Fellowship Program prior to her current role. She acted as the
principal investigator for several clinical trials and has been an
author of several publications.
This event is intended for institutional investors, sell-side
analysts, and business development professionals only. Please RSVP
in advance if you plan to attend, as space is limited. Members of
the media and the public are invited to participate via the live
webcast, which can be accessed through our company website at
https://nantkwest.com/nantkwest-key-opinion-leader-event/. The
event is expected to start at noon EST on Monday, December 2,
2019.
About NantKwest
NantKwest (NK) is an innovative, clinical-stage immunotherapy
company focused on harnessing the power of the innate immune system
to treat cancer and virally induced infectious diseases. We are the
leading producer of clinical dose forms of off-the-shelf Natural
Killer (NK) cell therapies. Our activated NK cell platform is
designed to destroy cancer and virally infected cells from the
body. The safety of our optimized, activated NK cells, as well as
their activity against a broad range of cancers, have been tested
in phase I clinical trials in Canada and Europe, as well as in
multiple phase I and II clinical trials in the United States. By
leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of
multiple, clinical-stage, immuno-oncology programs, NantKwest’s
goal is to transform medicine by delivering living drugs in a bag
and bringing novel NK cell-based therapies to routine clinical
care. NantKwest is a member of the NantWorks ecosystem of
companies. For more information, please visit
https://nantkwest.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements include statements concerning or
implying that NantKwest will be successful in improving the
treatment of cancer. Risks and uncertainties related to this
endeavor include, but are not limited to, obtaining FDA approval of
NantKwest’s NK cells as well as other therapeutics as part of the
NANT Cancer Vaccine platform as a cancer treatment.
Forward-looking statements are based on management's current
expectations and are subject to various risks and uncertainties
that could cause actual results to differ materially and adversely
from those expressed or implied by such forward-looking statements.
Accordingly, these forward-looking statements do not constitute
guarantees of future performance, and you are cautioned not to
place undue reliance on these forward-looking statements.
These and other risks regarding NantKwest’s business are
described in detail in its Securities and Exchange Commission
filings, including in NantKwest’s Quarterly Report on Form 10-Q for
the quarter ended September 30, 2019. These forward-looking
statements speak only as of the date hereof, and we disclaim any
obligation to update these statements except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191127005192/en/
Jen Hodson 562-397-3639 Jen@nant.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024